You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
翰宇藥業(300199.SZ)決定終止回購公司股份
格隆匯 12-31 20:18

格隆匯12月31日丨翰宇藥業(300199.SZ)公佈,公司於2019年12月31日召開的第四屆董事會第十二次會議、第四屆監事會第九次會議審議通過了《關於終止回購公司股份的議案》,決定終止回購公司股份的事項。

之前公告披露,擬回購4億元-8億元的公司股份。截至公告日,公司股份回購專用賬户已累計回購股份3368.5704萬股,約佔公司總股本的3.6738%,最高成交價11. 60元/股,最低成交價5. 44元/股,累計支付總金額約3.19億元(不含交易費用)。

隨着醫藥體制改革深入,引導產業發展的政策重心向降低醫療費用、提高企業創新能力方向傾斜,化藥製造業面臨新的機遇與挑戰,創新藥未來突破趨勢明顯。公司目前所面臨的行業發展機遇、市場環境較回購方案確立時發生了較大變化,為把握行業發展趨勢,公司在堅持高端仿製藥的同時,積極推進在研發創新領域的佈局,積極儲備企業未來創新動力。同時受宏觀經濟等因素影響,市場流動性趨緊,外部融資環境較預期更為困難。在當前情況下繼續推進股份回購事宜,已不再符合公司現階段的發展戰略,不符合公司及全體股東的利益。為保證公司產業投入資金,把握行業發展機遇,從而為全體股東創造更大的價值回報,公司審慎決定終止回購公司股份。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account